We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ali4.5
Alirocumab (Praluent) Research
Mostly mechanism / observational
213 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Alirocumab (Praluent) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2012–2026.
Based on 213 studies · 62 meta-analyses · 129 RCTs
Confidence
High confidence
By outcome
LDL cholesterolLowers LDL-C ~50-60% on top of statins; ODYSSEY OUTCOMES reduced major adverse cardiovascular events after recent acute coronary syndrome · Weeks (events: months to years)
Mostly mechanism / observational125 studies
Cardiovascular outcomesLowers LDL-C ~50-60% on top of statins; ODYSSEY OUTCOMES reduced major adverse cardiovascular events after recent acute coronary syndrome · Weeks (events: months to years)
Mostly mechanism / observational84 studies
Metabolic & lipid handling
Mostly mechanism / observational12 studies
Safety profile
Mostly mechanism / observational5 studies
Active research area
92 studies in the last 5 years · Latest meta-analysis: 2026